They talked about us in TF1, le monde, l’Echo republicain of 03/04/2020
“400,000 vials of neuromuscular blocking agents (curare) are delivered to hospitals in one weekend. . .
Interview with Luc Lamirault, CEO of Medipha Santé :
“Among the products we market, we have three generic references of curare (neuromuscular blocking agents)-curare based drugs used in intensive care units and for anesthesia during surgery. These are Rocuronium, Cisatracurium and Atracurium. Thanks to our stock, we have been able to deliver to 150 hospitals and clinics. They received 400,000 ampoules. We launched first curare at the beginning of 2019 and the next two at the end of the same year … We are a small company that is developing well but we were not prepared to cope with the current demand. We expanded our premises but the sharp increase in demand due to the coronavirus pandemic put us in the spotlight.
This medicine is based on European know-how: The manufacture of these sterile and injectable products is carried out in Slovakia, Latvia and Spain. Distribution and invoicing are carried out in France. Production lead times can be up to two months. Another obstacle, at the end of the chemical manufacturing process, the molecule must be transported refrigerated between 2 and 8 degrees, which complicates its transport. It is therefore difficult in these conditions to imagine rapid and massive production in the midst of a health emergency situation. »